Navigation Links
Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com
Date:7/13/2014

Dallas, Texas (PRWEB) July 13, 2014

Epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in 2023, at an Annual Growth Rate (AGR) of 4.35%, during the forecast period. In 2023, the US will have the highest number of diagnosed incident cases of aGVHD in the 6MM, with 4,989 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of aGVHD, with 704 diagnosed incident cases.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for the diagnosed incidence of HSCTs (including first, multiple, and re-transplants), segmented by transplant type (autologous and allogeneic), and the diagnosed incidence of GVHD in diagnosed incident cases of first HSCTs in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). GlobalData epidemiologists also provide a forecast for the four-year diagnosed prevalent cases of aGVHD and the five-year diagnosed prevalent cases of cGVHD in the 6MM. To forecast the diagnosed incident cases of HSCTs and the diagnosed incident and diagnosed prevalent cases of GVHD in the 6MM, GlobalData epidemiologists selected nationally-representative, population-based studies that provided the diagnosed incidence and the overall survival (OS) rates for HSCTs and GVHD in the 6MM.

Complete Report Available @ http://www.reportsnreports.com/reports/291525-epicast-report-graft-versus-host-disease-epidemiology-forecast-to-2023.html .

Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes (Hymes et al., 2012). The global distribution of GVHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GVHD prophylaxis pre- and/or post-transplantation. Around 30–70% of HSCT recipients will develop aGVHD, and another 30–70% will develop cGVHD independent of aGVHD (Arora et al., 2011; Champlin et al., 2000; Hymes et al., 2012; Jagasia et al., 2012; Joseph et al., 2008; Przepiorka et al., 1999). GVHD can be unpleasant and reduces the quality of life following HSCT, and in severe forms, significantly increases the risk of non-relapse mortality (Hymes et al., 2012; Wood et al., 2013). The number of persons with GVHD will continue to increase with the increase in survival of patients with GVHD and the increase in the number of patients who are at risk of developing aGVHD and cGVHD due to the increase in the number of allogeneic HSCTs performed worldwide (Joseph et al., 2008; Lee et al., 2003; Wood et al., 2013).

Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=291525 .

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for the diagnosed incidence of HSCTs (including first, multiple, and re-transplants), segmented by transplant type (autologous and allogeneic), and the diagnosed incidence of GVHD in diagnosed incident cases of first HSCTs in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). Epidemiologists also provide a forecast for the four-year diagnosed prevalent cases of aGVHD and the five-year diagnosed prevalent cases of cGVHD in the 6MM. To forecast the diagnosed incident cases of HSCTs and the diagnosed incident and diagnosed prevalent cases of GVHD in the 6MM, epidemiologists selected nationally-representative, population-based studies that provided the diagnosed incidence and the overall survival (OS) rates for HSCTs and GVHD in the 6MM.

Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=291525 .

Similarly, epidemiologists forecast an increase in the diagnosed incident cases of cGVHD in the 6MM, from 7,359 diagnosed incident cases in 2013 to 10,485 diagnosed incident cases in 2023, at an AGR of 4.25% during the forecast period. In 2023, the US will have the highest number of diagnosed incident cases of cGVHD in the 6MM, with 4,425 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of cGVHD, with 648 diagnosed incident cases. Epidemiologists held the diagnosed incidence of aGVHD and cGVHD constant throughout the forecast period; therefore, changes in the diagnosed incidence of allogeneic HSCTs in the respective markets, in combination with population changes, are driving the increase in the diagnosed incident cases of aGVHD and cGVHD.

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.

Read the full story at http://www.prweb.com/releases/graft-versus-host-disease/market-to-2023/prweb12012246.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Certain types of graft-versus-host disease may increase risk of death, Moffitt researcher says
2. New genetic clues to why most bone marrow transplant patients develop graft-versus-host disease
3. Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com
4. Culling Deer Herd Curbs Lyme Disease, Study Says
5. Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner
6. Growing up on a livestock farm halves the risk of inflammatory bowel diseases
7. Sleep disturbances, common in Parkinsons disease, can be early indicator of disease onset
8. Telemedicine for patients with chronic liver diseases
9. Penn study finds living kidney donation does not increase risk of death or heart disease for older
10. Growing old with HIV: Age-related diseases are bigger problem for African American women
11. Boston University researchers receive NIH funding for genetic research in Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: